Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLD-2660 in Idiopathic Pulmonary Fibrosis
NCT04244825Phase 2Withdrawn
- Sponsor
- Blade Therapeutics, Inc.
- Start
- Dec 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dazcapistat in idiopathic pulmonary fibrosis (IPF) (8 cohorts), sponsored by Blade Therapeutics, Inc. Primary endpoints: Observed changes in Integrin-Linked Kinase at 58 days, Observed changes in spectrin at 58 days and 2 more. Planned start Dec 2019; status: withdrawn.
02
Drugs
dazcapistat
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04244825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04244825.